NEW YORK, Oct 24 – Orchid BioSciences has purchased an option to co-develop and co-commercialize DNAPrint genomics’ SNP-disease associations and other intellectual properties, the companies said Tuesday.
The option provides Orchid exclusive rights to negotiate partnership terms with DNAPrint for existing and future products and properties, including genetic algorithms, software, and information resources such as SNP and haplotype associations with complex human traits and diseases.
Other terms of the agreement were not disclosed.
DNAPrint is developing genetic analytics and information resources for personalized medicine. The company aims to provide practitioners of genomic research and personalized medicine with a comprehensive system for complex trait dissection and patient classification.